Teva 2025: How Much of Cash Generation Is Really Organic
Teva reports $2.396 billion of free cash flow in 2025, but more than half of that number did not come from operating cash flow after capex. It came from collections tied to the European receivables securitization program and from divestitures, while operating cash itself also benefited from a one-off $500 million milestone and active working-capital management.
The main article argued that Teva has already moved beyond pure balance-sheet survival. Innovation is working, immediate credit pressure is lower, but the company still has not proved that deleveraging is becoming clean. This follow-up isolates only the cash question: how much of the $2.396 billion Teva presents as free cash flow in 2025 really came from the operating business, and how much came from receivables monetization, one-off milestone cash and active working-capital management.
The answer is not that the number is unreal. The cash is real. But it is not all the same kind of cash. In Teva’s bridge, operating cash flow, collections from beneficial interests created in the European securitization program, and asset-sale proceeds all sit under one free-cash-flow headline. That is a disclosed and legitimate definition. The analytical problem is different: if all of those dollars are treated as interchangeable, the market gets too generous a read on organic cash generation.
Four points frame the issue:
- More than half of reported free cash flow did not come from operating cash flow after capex. Out of $2.396 billion, only $1.148 billion was operating cash flow less reported capex.
- The year-on-year improvement in operating cash flow leaned on a large one-off event. The two Sanofi milestone payments totaled $500 million, while total operating cash flow improved by only $402 million versus 2024.
- Teva explicitly says receivables and payables management are part of the cash outcome. The company says it accelerates collections, slows vendor payments and manages the timing of legal-settlement and tax payments, and that these choices can materially affect annual operating cash flow and leverage.
- The balance-sheet tools are still doing real work. The European DPP asset rose to $326 million, supplier-finance balances rose to $225 million, and reduced use of the U.S. securitization program pushed more receivables back onto the balance sheet.
What remains without the balance-sheet aids
The right starting point is to separate two different cash frames. The first is Teva’s own headline, $2.396 billion of free cash flow. The second, which is more relevant if the question is how much cash the existing business produced before balance-sheet aids, is operating cash flow less reported capex. On that basis the number falls to $1.148 billion.
| Cash frame | 2025 | What it actually includes |
|---|---|---|
| Free cash flow as Teva presents it | 2,396 | Operating cash flow, collections from beneficial interests under EU securitization, divestitures, less capex |
| Operating cash flow | 1,649 | Cash generated before capital spending |
| Operating cash flow less capex | 1,148 | The cleaner layer for testing recurring cash generation from the existing business |
| Gap between the headline and the cleaner layer | 1,248 | Mainly securitization collections and divestiture proceeds |
This is not just a one-year issue. In 2024 Teva reported $2.068 billion of free cash flow while operating cash flow less capex was only $749 million. So the architecture improved in 2025, but it did not become clean.
That gap matters even more because the cleaner 2025 layer was not fully recurring either. Teva says the increase in operating cash flow mainly reflected milestone payments received when Phase 3 studies for duvakitug were initiated, and those milestone payments totaled $500 million in 2025. That is larger than the entire year-on-year increase in operating cash flow, which was $402 million. At the same time, legal settlement payments were higher. So 2025 does show that Teva had more cash sources than in 2024, but it still does not prove that a new recurring cash floor is already in place for 2026.
That distinction is the core of the follow-up. Milestone cash is real cash, but it is not the same thing as cash generated from repeat prescription demand or from structurally stronger margins. The right question is not whether the money came in. It is which part of it can be expected to come back without another development trigger.
Working capital is still being managed, not simply converted
Teva is explicit about this. In the liquidity discussion the company says it seeks to improve working-capital efficiency through inventory optimization, faster collection, slower vendor payments, and timing decisions around legal settlements, tax authorities and other items. It adds that those decisions have had, and may continue to have, a material impact on operating cash flow and leverage measurement.
That is not boilerplate. It is a direct statement that annual cash generation depends partly on balance-sheet timing choices, not only on the earning power of the business.
The detailed numbers support that point. At year-end 2025, receivables net stood at $3.709 billion versus $3.059 billion a year earlier, and inventory rose to $3.179 billion from $3.007 billion. In the company’s own working-capital commentary, the increase in receivables is linked in part to reduced utilization of the U.S. securitization program, while the inventory increase is tied mainly to foreign exchange. Payables, meanwhile, rose to $2.531 billion from $2.203 billion.
The cash-flow statement is even sharper. Changes in operating assets and liabilities consumed $1.366 billion of cash, including a $173 million use in receivables. Inventory actually released $152 million, but other assets alone absorbed $1.330 billion. That is exactly why Teva’s cash generation cannot be read through a single line. The cash outcome sits on several moving balance-sheet layers at once.
Securitization and supplier finance support liquidity, but they do not make it organic
In Europe, Teva continues to use its receivables securitization program, which was extended through August 2026. The structure is straightforward: the company sells receivables, gets part of the purchase price upfront in cash, and keeps the remainder as a DPP asset, a deferred purchase price receivable. By year-end 2025 that DPP asset stood at $326 million, up from $231 million in 2024, and sold receivables outstanding net of DPP stood at $677 million versus $626 million a year earlier.
During 2025 Teva collected $1.214 billion from those beneficial interests, while also recording $1.278 billion of new beneficial interests obtained in exchange for securitized receivables. So what appears in the free-cash-flow headline as extra cash is, to a large extent, part of a standing receivables-monetization cycle. It is real cash, but it rests on a working-capital financing mechanism rather than on clean operating cash generation.
In the U.S. the story runs in the opposite direction but teaches the same lesson. The AR Facility was extended in November 2025 for another three years, with the commitment amount unchanged at $950 million. But by year-end 2025 the amount of receivables sold and derecognized had fallen to $794 million from $895 million, while receivables pledged as seller guarantee and therefore still carried in receivables rose to $799 million from $558 million. Teva itself links the increase in receivables to reduced utilization of the U.S. program. In plain terms, when Teva leans less on U.S. receivables sales, more receivables come back onto the balance sheet and the operating-cash optics weaken.
The supplier side shows the same pattern of balance-sheet support. Teva runs supplier-finance programs under which suppliers may sell approved invoices to financial institutions, while Teva pays the stated amount on maturity, generally within 120 days from invoice receipt. At year-end 2025 the outstanding balance in these programs was $225 million, up from $158 million in 2024, and invoices confirmed during the year rose to $786 million from $533 million.
The nuance matters. Teva says the program does not require pledged assets or other guarantees from the company, and the balances remain classified within accounts payable. So this is not hidden debt pushed outside the balance sheet. Economically, though, it is still a tool that helps keep more cash inside the system for longer.
| Balance-sheet tool | 2024 | 2025 | What it says |
|---|---|---|---|
| Collections from EU securitization beneficial interests | 1,291 | 1,214 | A large cash line that remains outside operating cash flow |
| EU DPP asset | 231 | 326 | More receivables value remained parked as deferred purchase price |
| U.S. receivables sold and derecognized | 895 | 794 | Lower use of the U.S. program |
| U.S. receivables pledged as seller guarantee | 558 | 799 | More receivables stayed on the balance sheet |
| Supplier-finance balances | 158 | 225 | Greater support on the payables side |
Funding flexibility improved, but that only sharpens the organic-cash test
Teva has more room than it had a year ago. Debt fell to $16.807 billion from $17.783 billion, the $1.8 billion revolving credit facility was extended to April 29, 2028, and the December 2025 amendment set the maximum leverage ratio at 4.25x from Q4 2025 onward, with covenant suspension possible if Teva achieves investment-grade status and remains free of default. That is a real improvement in liquidity.
But this is where liquidity and organicity need to be separated again. In 2025 Teva repaid $4.112 billion of senior notes, loans and other long-term liabilities, while also issuing $2.298 billion of new senior notes net of issuance costs. So debt reduction did not come only from cash generated inside the business. Capital-market access and extended funding lines remained part of the solution.
That is exactly why 2026 becomes a stricter test. As immediate liquidity risk falls, the market can afford to be more selective. It will focus less on whether Teva can access cash, and more on whether, without another $500 million milestone and without heavier reliance on securitization and balance-sheet timing, operating cash flow after capex can really support legal payments, pipeline investment and lower debt at the same time.
The conclusion of this continuation is therefore sharper than in the main article. Teva is no longer fighting for immediate liquidity, but it still has not proved that its new cash engine is organic enough on its own. At the end of 2025 the cash is there, flexibility is better and the financial system is less strained. Even so, too much of the cash headline still rests on one-off development cash, receivables monetization and active payment-and-collection management. Until that layer starts shrinking, 2025 reads more like a year of buying time than a year of proving a clean cash engine.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.